programs combine antibody engineering, protein degradation technologies, and targeted drug delivery approaches to address difficult-to-treat cancers. The company’s proprietary FireLink platform is designed to expand the range of payloads that can be used in ADCs, including protein-degrading agents that are traditionally challenging to deliver selectively to tumors. By linking these payloads to antibodies that recognize cancer-specific targets, Firefly Bio aims to enhance the effectiveness of targeted oncology treatments and broaden the therapeutic potential of ADCs.

Firefly Bio conducts research and development activities across target discovery, antibody engineering, conjugation technologies, translational science, and preclinical drug development. Its programs focus on solid tumors and other oncology indications where existing treatment options may be limited. The company’s scientific approach integrates expertise in cancer biology, medicinal chemistry, protein engineering, and bioconjugate development. In addition to advancing its internal pipeline, Firefly Bio collaborates with researchers, investors, and industry partners to support the development of novel cancer therapies. Its team includes scientists and drug developers with experience in oncology research, ADC development, and biopharmaceutical commercialization.